Lumen Bioscience Expands Biologics Manufacturing Capacity with Lease of Historic Seattle Bakery | News

SEATTLE, July 15, 2021 / PRNewswire / – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biological drugs for common diseases, today announced the future expansion of its biological manufacturing capacity through a lease to occupy a former bakery in the Fremont-Wallingford suburb Seattle.

After being reconfigured by Lumen, the space will house a greatly expanded cGMP-grade manufacturing facility to produce the larger quantities of spirulina-based biological medicines needed for Lumen Bio’s upcoming clinical trials.

“We are excited to usher in a new era with this building that will allow us to meet the needs of several large clinical trials scheduled to begin next year,” said Craig Behnke, Executive Vice President, Production / Development at Lumen Bio. “This factory has been producing food safely for decades, and it’s not a big leap from making sourdough to spirulina-based medicines. In cooperation with an experienced team of architects and contractors, we plan to put the new system into operation within the next six months. “

The building was constructed in 1929 as the headquarters of the Buchan Baking Company. It was operated by the Essential Baking Company from the 1990s until modern times. Essential’s commercial business grew beyond the larger area in just a few years, but it operated a coffee shop off a corner of the building until March 2020 when Essential decided to focus more on its bakery wholesale business.

“We are pleased to be able to expand our presence in an ideal location opposite our current headquarters and laboratory. Our team and drug development efforts are growing rapidly and this is a much needed development to support this expansion, ”said Brian Finrow, CEO of Lumen.

over Lumens

Lumen Bioscience discovers, develops, and manufactures biological medicines for common diseases worldwide, many of which do not currently have effective treatments. The company’s unique drug development and manufacturing platform has the potential to transform the biologics industry through greater speed, mass market size, and exponentially lower cost than previous approaches. Lumen’s clinical pipeline includes investigational biologics for C. difficile infection, cardiometabolic disease, inflammatory bowel disease, Covid-19, norovirus, and travelers’ diarrhea. Further information can be found at: www.lumen.bio.

Media contact:

Julie Rathbun

+1.206.769.9219

jrathbun@lumen.bio

View original content to download multimedia: https://www.prnewswire.com/news-releases/lumen-bioscience-expands-biologics-manufacturing-capacity-with-lease-of-historic-seattle-bakery-301334500.html

SOURCE Lumen Bioscience